OSF Ventures

OSF Ventures, founded in 2015 and based in Peoria, Illinois, is the corporate venture arm of OSF HealthCare. It focuses on investing in companies that aim to enhance patient outcomes, improve patient experiences, and lower healthcare costs. OSF Ventures adopts a collaborative approach, combining financial investment with strategic partnerships to foster innovation in health information technology, medical devices, therapeutics, diagnostics, and technology-enabled delivery sectors. The organization is rooted in the mission and values of OSF HealthCare, emphasizing compassion, integrity, teamwork, and stewardship. By employing principles of humble curiosity and thoughtful risk-taking, OSF Ventures seeks to challenge conventional practices and advocate for more compassionate healthcare solutions for all.

Kevin Fahey

Founder and Director

Stan Lynall

Vice President of Venture Investments

Robert Sehring

Founder and CEO

Mayank Taneja

Vice President, Venture Investments

Past deals in Wearables

Cala Health

Series C in 2024
Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.

Epitel

Series A in 2022
Epitel is a digital health company focused on developing a wearable, wireless EEG monitoring platform aimed at improving seizure detection. The company offers a brain health monitoring device that accurately identifies abnormal brain activities using a proprietary cloud-based wearable sensor system combined with advanced artificial intelligence technologies. This innovative approach provides accessible, affordable, and reliable electrographic seizure detection, allowing physicians, caregivers, and patients with neurological disorders to gain valuable insights into brain health. By enhancing the quality of life and care for individuals affected by these conditions, Epitel strives to make significant contributions to the field of digital health.

Current Health

Series B in 2021
Current Health help healthcare reduces risk & cost by monitoring, managing, and engaging patients at home.

Renovia

Series C in 2021
Renovia Inc. was a Boston-based healthcare company founded in 2016, focused on developing prescription digital therapeutics for pelvic floor disorders. The company aimed to enhance the lives of women suffering from conditions such as stress, mixed, and urgent urinary incontinence, including overactive bladder. Renovia's innovative device provided a clinically proven, non-surgical, drug-free treatment option, allowing for real-time visualization of pelvic movement during muscle training, thereby facilitating effective therapy. However, in late 2022, Renovia ceased operations following a strategic review by its investors, which included the consideration of a potential sale. In January 2023, most of the company's assets, including its intellectual property, were acquired by Axena Health, Inc.

Renovia

Series B in 2018
Renovia Inc. was a Boston-based healthcare company founded in 2016, focused on developing prescription digital therapeutics for pelvic floor disorders. The company aimed to enhance the lives of women suffering from conditions such as stress, mixed, and urgent urinary incontinence, including overactive bladder. Renovia's innovative device provided a clinically proven, non-surgical, drug-free treatment option, allowing for real-time visualization of pelvic movement during muscle training, thereby facilitating effective therapy. However, in late 2022, Renovia ceased operations following a strategic review by its investors, which included the consideration of a potential sale. In January 2023, most of the company's assets, including its intellectual property, were acquired by Axena Health, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.